About Lucid Diagnostics Inc.
https://www.luciddx.comLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
CEO
Lishan Aklog
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:4.52M
Value:$5.61M
MASTERS CAPITAL MANAGEMENT LLC
Shares:4M
Value:$4.96M
BLACKROCK, INC.
Shares:3.67M
Value:$4.55M
Summary
Showing Top 3 of 89
About Lucid Diagnostics Inc.
https://www.luciddx.comLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.21B ▲ | $11.27B ▲ | $-10.4B ▼ | -858.55% ▼ | $-0.1 ▼ | $-9.95B ▼ |
| Q2-2025 | $1.16M ▲ | $10.76M ▼ | $-4.44M ▲ | -381.69% ▲ | $-0.08 ▲ | $-4.21M ▲ |
| Q1-2025 | $828K ▼ | $11.76M ▲ | $-26.91M ▼ | -3.25K% ▼ | $-0.52 ▼ | $-26.68M ▼ |
| Q4-2024 | $1.2M ▲ | $11.43M ▲ | $-11.54M ▲ | -964.16% ▲ | $-0.2 ▲ | $-11.31M ▲ |
| Q3-2024 | $1.17M | $11.18M | $-12.37M | -1.06K% | $-0.25 | $-12.15M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $47.33M ▲ | $53.2M ▲ | $27.36M ▼ | $25.84M ▲ |
| Q2-2025 | $31.12M ▲ | $38.67M ▲ | $30.81M ▼ | $7.86M ▲ |
| Q1-2025 | $25.24M ▲ | $32.8M ▲ | $38.17M ▲ | $-5.38M ▼ |
| Q4-2024 | $22.36M ▲ | $30.71M ▲ | $25.32M ▲ | $5.39M ▼ |
| Q3-2024 | $14.49M | $22.6M | $16.26M | $6.34M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-10.4M ▼ | $-10.89M ▼ | $-28K ▼ | $27.13M ▲ | $16.21M ▲ | $-10.92M ▼ |
| Q2-2025 | $-4.44M ▲ | $-10.55M ▲ | $-25K ▲ | $16.46M ▲ | $5.88M ▲ | $-10.57M ▲ |
| Q1-2025 | $-26.91M ▼ | $-12.46M ▼ | $-93K ▲ | $15.44M ▼ | $2.88M ▼ | $-12.56M ▼ |
| Q4-2024 | $-11.54M ▲ | $-9.87M ▲ | $-259K ▲ | $18M ▲ | $7.87M ▲ | $-10.13M ▲ |
| Q3-2024 | $-12.37M | $-10.18M | $-350K | $94K | $-10.43M | $-10.53M |
CEO
Lishan Aklog
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:4.52M
Value:$5.61M
MASTERS CAPITAL MANAGEMENT LLC
Shares:4M
Value:$4.96M
BLACKROCK, INC.
Shares:3.67M
Value:$4.55M
Summary
Showing Top 3 of 89